Vir Biotechnology says FDA grants Fast Track status to prostate cancer drug VIR-5500
VIR•Vir Biotechnology said the FDA granted Fast Track designation to VIR-5500 for late-line metastatic castration-resistant prostate cancer. The company expects to start pivotal Phase 3 trials in 2027.
1. Fast Track designation
Vir Biotechnology said the FDA granted Fast Track designation to VIR-5500 for late-line metastatic castration-resistant prostate cancer. The program is co-developed with Astellas under a global collaboration.
2. Phase 3 plans
Vir expects to start pivotal Phase 3 trials in 2027.
